Vir Biotechnology Names Jason O’Byrne CFO
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
- Latest
- Trending
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
NBT Bancorp's acquisition of Evans Bancorp expands its reach in New York, aims to boost market share and diversify assets.
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
Oxylus Energy secures $4.5M to advance its innovative conversion of CO2 to green methanol, aiding global decarbonization efforts.
Trinity Biotech appoints Adrian Donohue as CCO, aiming for growth with new HIV product and CGM market entry.
Analog Devices reports impressive Q3 earnings and revenue, surpassing forecasts and projecting a positive Q4 outlook.
The IEA reports a continued decline in Chinese oil demand amid weakened industrial activity and a struggling economy.
Roivant reports strong clinical progress, with significant Phase 3 study completions, revenue growth, and financial strength.
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.